Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
- Positive 24-month data from ongoing Phase 2 TOPAZ trial extension supports potential benefit of apitegromab for patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)- Actively enrolling in pivotal Phase 3 SAPPHIRE clinical trial for apitegromab- Discovery pipeline advancements made for LTBP-TGFβ1 target to tre...
Source: pharmiweb.com